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Elastin Fragments Induce IL-1b Upregulation
via NF-jB Pathway in Melanoma Cells
Romain Debret1, Richard R. Le Naour2, Jean-Michel Sallenave3, Aurelie Deshorgue1,
William G. Hornebeck1, Moncef Guenounou2, Philippe Bernard1 and Frank D. Antonicelli1
In a previous work, we reported the influence of elastin fragments (EFs) on matrix metalloproteinases-2 and -14
expression and activation in melanoma cells in vitro. We hypothesized that EFs might also modulate expression
of other mediators involved during melanoma progression. Therefore we investigated the contribution of EFs
on IL-1b expression, a cytokine playing a key role in melanoma cells activation. Our results evidenced that high
tumorigenic melanoma cells (M3Da cells) treated with EFs led to IL-1b mRNA and protein upregulation. The
effects of EFs on M3Da cells were found to be mediated by receptor (spliced galactosidase) occupancy, as being
suppressed by lactose and reproduced by cell stimulation with the VGVAPG peptide. Binding of EFs to their
receptor induced a rapid activation of extracellular signal-regulated kinase 1/2; and p38 mitogen-activated
protein kinase pathways. However, these pathways were not associated with IL-1b mRNA upregulation by EFs.
Concomitantly, we demonstrated that EFs stimulation induced NF-kB nuclear translocation and DNA binding on
IL-1b promoter region whereas inhibition of NF-kB with the specific chemical inhibitor SN-50 or by
overexpression of IkB, the endogenous inhibitor of NF-kB pathway, totally abolished EFs-mediated IL-1b mRNA
overexpression. These results demonstrate that EFs induce NF-kB activation, leading to IL-1b upregulation in
invasive melanoma cells.
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INTRODUCTION
Accumulating evidence suggests an association of chronic
inflammation and tumor progression (Karin, 2005). Inflam-
matory mediators such as cytokines influence the ability of
tumor cells to grow and metastasize in its microenvironment
by modulating the expression of other cytokines/growth
factors. Melanoma cells behavior is particularly sensitive to
inflammatory mediators because these tumor cells express
and respond to a wide array of soluble factors (Lazar-Molnar
et al., 2000). Among the numerous pro-inflammatory factors,
IL-1b is particularly implicated in melanoma progression.
Most melanoma cells spontaneously produce this pleiotropic
cytokine that has been shown to exacerbate invasiveness,
adhesion, angiogenesis, and metastases spreading in many
experimental and in vivo models of melanomas (Dinarello,
1996). For instance, IL-1b promotes metastases by activating
cell adhesion on endothelial cells (Vidal-Vanaclocha et al.,
1996; Yano et al., 2003), and modulates expression and
activity of matrix metalloproteinases (MMPs) in stromal and
tumor cells contributing to matrix degradation (Xie et al.,
2003, 2004; Loffek et al., 2005). It has been shown that IL-1b
induces its own expression through a positive autoregulatory
loop implicating the recruitment of NF-kB pathway (Hiscott
et al., 1993). External stimuli also come from the tumor
microenvironment. Some macromolecules from extracellular
matrix (ECM) such as fibronectin, type I collagen, fibrin, and
laminin have been shown to induce IL-1b gene transcription
through mitogen-activated protein kinases (MAPK)-depen-
dent mechanisms (Roman et al., 1999).
Molecules from ECM constitute a physical barrier that
melanoma cells have to pass through by directional
proteolysis processes (Hornebeck et al., 2002). ECM remo-
delling implicates many enzymes of which matrix metallo-
proteinases correlate to an invasive phenotype of melanoma
in vitro, particularly MMP-2 expression is associated with
architectural disorders and melanoma progression (Hofmann
et al., 2005). In a previous study, we showed that invasive
melanomas were accompanied with intense fragmentation of
elastic fibers at their invasive fronts and that elastin fragments
(EFs) upregulated melanoma cells invasiveness through
MMP-2 activation (Ntayi et al., 2004). EFs are considered
as functional matrikines since they induce biological
activities on numerous cell types through their cell surface
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receptor (Duca et al., 2004). The elastin complex receptor is
composed of three subunits of which the elastin-binding
protein, also named spliced galactosidase (S-Gal) (for spliced
form of b-galactosidase), is a 59–67-kDa protein (Blood et al.,
1988; Hinek, 1996; Yamamoto et al., 2002). S-Gal binds
with high affinity the sequence VGVAPG that is repeated
several times in human elastin. This receptor also possesses
galactolectin properties, having the ability to fix b-galacto-
sugars such as galactose or lactose resulting in S-Gal
shedding from the cell surface; thus, preventing elastin
binding (Hinek et al., 1988). The extracellular-regulated
kinase (Erk) 1/2 MAPK pathway has been reported to be
involved in EFs-induced proliferation of human arterial
smooth muscle cells (Mochizuki et al., 2002) as well as in
upregulation of MMP-1 which also depends on the recruit-
ment of the transcription factor activator protein-1 (AP-1) in
human skin fibroblasts (Duca et al., 2002). In a recent study,
we reported that EFs activate the 1/2 Erk/AP-1 pathway
in human blood lymphocytes, and we demonstrated that
EFs induce T-helper type-1 polarization of T cells (Debret
et al., 2005).
In this study, we examined EFs-induced signalling path-
ways in melanoma cells and demonstrated that following
S-Gal occupancy, EFs-induced NF-kB DNA binding and
activation leading to IL-1b upregulation.
RESULTS
EFs increase IL-1b production in invasive melanoma cells
through its receptor (S-Gal)
Two melanoma cell lines, M1Dor and M3Da, presenting a
low and a high tumorogenic pattern, respectively, were
assessed for their ability to express the cytokine IL-1b. Basal
and EFs-activated IL-1b protein productions were investigated
by ELISA. Both cell lines expressed basal level of IL-1b
protein (Figure 1a). In invasive M3Da melanoma cells, EFs
treatment enhanced basal IL-1b protein level by 52%,
whereas M1dor cells did not respond to these peptides
(Figure 1a). ELISA results were confirmed by FACS analyses
(data not shown). In the two cell lines, reverse transcription-
PCR (RT-PCR) analyses showed that IL-1b mRNA level corre-
lated with protein productions in basal and EFs-activated
conditions (Figure 1b).
Presence of the elastin receptor (S-Gal) in both cell
lines was demonstrated by Western blot analyses using an
antibody raised against the specific amino-acid sequence
differencing S-Gal, described as the subunit surface receptor,
from b-Gal (Figure 2a). Endothelial cells (human umbilical
vein endothelial cells) membrane extracts were used as
positive control (Robinet et al., 2005). Implication of a
receptor-dependent transduction signal upon EFs stimulation
was then addressed with the VGVAPG peptide, which is the
minimal and specific elastin sequence binding on S-Gal.
Figure 2b shows that treatment of M3Da cells with VGVAPG
reproduced EFs effects on IL-1b mRNA in a dose-dependent
manner, whereas M1Dor cell were still not responsive (data
not shown). In these conditions of stimulation, specificity
of response was controlled using lactose, a galactosugar that
binds and inhibits the S-Gal subunit. Cells pretreatment with
lactose during 1 hour totally abolished the VGVAPG-en-
hanced IL-1b mRNA expression in M3Da cells, whereas
treatment with lactose alone had no effect on the cytokine
expression (Figure 2c).
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Figure 1. Influence of EFs on in vitro production and expression of IL-1b.
(a) Production of IL-1b in melanoma cells cultured in serum-free medium with
or without EFs (50 mg/ml) was determined by ELISA. (b) IL-1b mRNA
expression was assessed by semiquantitative PCR on cDNA obtained after
reverse transcription of total RNAs from melanoma cells treated or not for
4 hours with EFs. ELISA data are mean7SEM; *Po0.05.
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Figure 2. Positive regulation of IL-1b expression by EFs requires S-Gal
binding. (a) Presence of S-Gal protein at the surface of melanoma cells was
assessed by Western blot. Human umbilical vein endothelial cells were used
as positive control. (b) M3Da cells were stimulated with increasing doses of
VGVAPG for 4 hours before analysis of the IL-1b mRNA expression by
semiquantitative RT-PCR. (c) The role of S-Gal in overexpression of IL-1b
mRNA in response to EFs was studied by preincubating M3Da cells for 1 hour
with lactose (10 mM) prior stimulations with VGVAPG (50 mg/ml); total RNAs
were then analyzed by semiquantitative RT-PCR.
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Activation of MAPK by EFs is not responsible of IL-1b
up-regulation
In order to elucidate the mechanisms involved in EFs-induced
IL-1b overexpression in M3Da cells, we analyzed the
activation of the MAPK pathways which are known to be
recruited by matrix compounds for IL-1b gene regulation.
Investigation of MAPKs by Western blot revealed that both
Erk 1/2 and p38 kinases were rapidly activated (within
5 minutes) in M3Da cells under EFs treatments (Figure 3a). In
line with these results, we examined the DNA-binding ability
of the transcription factor AP-1 by gel shift assays since this
promoter activator is dependent of MAPKs activation.
Specificity of DNA binding was addressed by gel shift
competition using 50-fold excess of specific and non-specific
unlabelled probes. This analysis shows that AP-1 DNA
binding was increased after a 1 hour stimulation period with
EFs in M3Da cells (Figure 3b).
The Erk 1/2 and p38 transduction pathways were then
assessed for their implication in the IL-1b increased expres-
sion upon EFs stimulation. Inhibition of the Erk 1/2 and p38
pathways was performed by cell pre-incubation with the
specific pharmacological inhibitors U0126 and SB203580,
respectively, for 1 hour prior to EFs stimulation. Figure 3c
shows that both inhibitors failed to inhibit EFs effects on IL-1b
mRNA expression compared to control. Additionally, we
observed that Erk 1/2 inhibition induced IL-1b expression.
Effects of EFs on NF-jB activation in melanoma cells
Since both Erk 1/2 and p38 MAPKs pathways were not
involved in EFs-increased IL-1b expression, we investigated
NF-kB activation, which is another important signalling
pathway involved in IL-1b regulation. NF-kB pathway
activation was first investigated by gel shift assays, performed
with a consensus probe for NF-kB DNA binding (Figure 4a).
Kinetics analysis revealed a time-dependent increase of
NF-kB DNA binding in M3Da cells in response to EFs
stimulation. Specificity of DNA binding was addressed by
-38 kDaAnti-(p)-p38
Anti-(p)-Erk1/2
Ponceau S
0
0
EFs
U0126
SB203580
15 30 60 SpeN. Spe
5 10 15
Competitions
AP-1
IL-1 mRNA
18S RNA
Free probe
30 60 (minutes)Stimulation
time by EFs
Stimulation time
by EFs (minutes)
-44 kDa
-42 kDa
−
−
−
−
+
−
+
+
−
+
+
−
+79% +114% +73%
}
a
b
c
Figure 3. Regulation of MAPK pathways and AP-1 DNA binding by EFs and
their consequences on IL-1b mRNA expression in melanoma cells. (a) Cell
lysates from melanoma cells treated by EFs for different durations were
separated by SDS-PAGE under reducing conditions, and activation of Erk 1/2
and p38 were determined by Western blot. Blots were stained with Ponceau S
to ensure equal protein amount loadings (b) AP-1 DNA-binding activity from
nuclear protein extracts of EFs-stimulated melanoma cells was assessed by
electrophoretic mobility shift assay. Specificity of DNA binding was assessed
by competitions using specific and non-specific unlabelled probes. (c) The
role of MAPK recruitment by EFs in IL-1b mRNA overexpression mechanism
was studied by preincubating M3Da cells for 1 h with U0126 (10mM) or
SB203580 (5 mM) prior 4 hours stimulations with EFs; total RNAs were then
analyzed by semiquantitative RT-PCR.
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Figure 4. Activation of NF-jB pathway by EFs in M3Da cells. (a) NF-kB
DNA-binding activity from nuclear protein extracts of EFs-stimulated
melanoma cells was assessed by electrophoretic mobility shift assay.
Specificity of DNA binding was assessed by competitions using specific and
non-specific unlabelled probes. (b) Identification of NF-kB complex present in
the nucleus of M3Da cells was studied by super-shift assays where nuclear
proteins were incubated or not with antibodies specific for p50 or p65 NF-kB
subunits. (c) Nuclear protein extracts from M3Da cells stimulated by EFs for
different durations were separated by SDS-PAGE under reducing conditions,
and presence of p50 or p65 was determined by Western blot. (d) M3Da cells
were infected by Ad-luc (100 PFU/cell) prior stimulations with EFs overnight;
relative luciferase activity was measured with luminometer in presence of
appropriate substrate. Data are mean7SEM; *Po0.05.
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gel shift competition using 50-fold excess of specific and non-
specific unlabelled probes. In order to confirm the nature
of the NF-kB complexes, we used antibodies for the p50
and p65 NF-kB subunits in supershift assays (Figure 4b). We
demonstrated that NF-kB DNA binding was related to both
complexes p50/p50 and p50/p65 since both antibodies
supershifted the NF-kB bands (black arrows in lanes 2 and
3). To confirm this NF-kB activation upon EFs stimulation, we
next analyzed the influence of EFs on p50 and p65 (NF-kB
subunits) accumulation in the nucleus compartment of M3Da
cells. Western blot analyses showed an increase of both p50
and p65 entities under stimulated conditions (Figure 4c). To
assess whether the induction of NF-kB by EFs was efficient to
induce gene expression, we infected M3Da cells with an
adenovirus (Ad-luc) containing the gene coding for luciferase
under control of a chimerical promoter constituted of three
NF-kB sites in tandem repeats. The tandem repeats structure
permits to raise the sensitivity of the detection and the
luciferase gene construct is currently used as a reporter gene.
Increase of luciferase activity in cells treated with EFs versus
untreated cells (54%) demonstrated the biological activity of
the NF-kB DNA-binding complexes (Figure 4d).
NF-jB activation is implicated in IL-1b upregulation by EFs in
M3Da melanoma cells
We next sought a relationship between EFs-induced NF-kB
and the effect of these peptides on IL-1b upregulation. To that
purpose, we first used a specific inhibitor (SN-50) of the
translocation of the NF-kB p50 subunit to the nucleus.
Consequently to NF-kB inhibition, EFs were unable to
increase IL-1b mRNA expression whereas the use of an
inactive SN-50 mutant (SN-50M) did not affect EFs-increased
IL-1b mRNA (Figure 5a). To further demonstrate the implica-
tion of NF-kB pathway in IL-1b expression, cells were
infected with an Ad overexpressing IkBa, a physiological
NF-kB inhibitor. The lack of EFs effects on IL-1b mRNA
expression in these conditions of inhibition compared to an
Ad expressing a non-relevant protein (Ad-ova) used as a
control, confirmed the relationship between NF-kB activation
and IL-1b expression upon EFs stimulation in M3Da cells
(Figure 5b).
NF-jB DNA binding is increased during IL-1b promoter
activation by EFs
To analyze a direct involvement of NF-kB in IL-1b expression
at the genomic level, chromatin immunoprecipitation assay
was performed in presence or absence of EFs. To that matter,
we analyzed the occupancy of the NF-kB response elements
present in the distal and the proximal part of the IL-1b
promoter. Chromatin was immunoprecipitated with an anti-
body raised against the NF-kB p50 subunit, and the distal and
proximal domain of the IL-1b promoter containing the NF-kB
sites were examined by RT-PCR. This experiment showed
that EFs increased the NF-kB p50 subunit DNA binding to the
proximal (300) and the distal (3,094) elements of the IL-1b
promoter after a 2 hours incubation period whereas immuno-
precipitation using a non-specific IgG as a control resulted in
faint bands in treated and untreated cells (Figure 6a).
Since both NF-kB and AP-1 were induced and trans-
located to the nucleus upon EFs stimulation, and the two
binding sequences are placed side by side in the IL-1b distal
promoter, we therefore examined the ability for these two
factors to bind concomitantly to their own DNA sequence by
gel shift assay. To that purpose, we carried out competition
assays between radio-labelled DNA consensus sequences
for AP-1 and NF-kB, and specific unlabelled DNA probes
encompassing the AP-1, NF-kB or both sites that mimic the
upstream enhancer element of IL-1b promoter (Goto et al.,
1999) (Figure 6b). The two graphics express the percentage
of the consensus DNA-binding inhibition induced by each
specific unlabelled probe. Competition experiments using
the AP-1 consensus probe revealed that the AP-1 sequence
(Probe 3) corresponding to the IL-1b promoter strongly
reduced AP-1 DNA binding to the consensus probe.
However, if the NF-kB sequence (Probe 2) had hardly any
effect on its own, it decreased the inhibitory effect of the AP-1
sequence when present on the same probe (Probe 1). By
contrast, analysis of competition experiments with the NF-kB
consensus probe revealed not only that the AP-1 sequence
corresponding to the IL-1b promoter had no effect by itself
but strongly increased the DNA-binding activity on the
NF-kB site, observed by an increased inhibitory effect, when
co-localized on the same probe (Probe 1).
DISCUSSION
It is now well established that ECM participates to the stroma/
tumor interactions and there is increasing evidence that
fragments issued from ECM degradation modulate expression
of soluble factors and proteases in neoplastic and stromal
cells (Maquart et al., 2005). Using cryosections of primary
melanomas we have previously shown that elastic fibers are
strongly degraded at the invasive front of aggressive tumors in
which the expression of S-Gal was prominent (Ntayi et al.,
2004). In the present study, we show for the first time that EFs
increase the expression of IL-1b cytokine in the more invasive
EFs
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Figure 5. Influence of NF-jB recruitment by EFs on IL-1b mRNA expression.
(a) M3Da cells were preincubated with cell-permeable peptides SN-50 (50 mM)
and SN-50M (50mM) for 1 hour prior 4 hours stimulations with EFs; total RNAs
were then analyzed by semiquantitative RT-PCR. (b) M3Da cells were infected
with Ad overexpressing IkBa (100 PFU/cell) or Ad-ova (100 PFU/cell)
prior 4 hours stimulations by EFs; total RNAs were then analyzed by
semiquantitative RT-PCR.
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melanoma cells (M3Da) through the S-Gal receptor as being
suppressed by lactose and reproduced by cell stimulation
with the VGVAPG peptide. This overexpression of IL-1b was
not observed in the less invasive cells (M1Dor) neither upon
EFs nor VGVAPG stimulation, although the S-Gal receptor
was present at the membrane surface. This differential
response to EFs on IL-1b expression suggests a difference in
the capacity of these cells to transduce a signal from the
S-Gal receptor, which is supported by our previous study
showing that EFs increased MMP-2 expression and invasive
properties only in the M3Da melanoma cells (Ntayi et al.,
2004).
Based on our previous work with EFs in human skin
fibroblasts (Duca et al., 2002), and others in arterial smooth
muscle cells (Mochizuki et al., 2002), we hypothesized
that induction of IL-1b gene expression by this matrikine
was dependent on the Erk 1/2 MAPK pathway activation.
Experiments on transduction pathways cascades revealed
for the first time that EFs activated not only the MAPK/Erk
1/2 pathways but also activated the MAPK/p38 pathway in
EFs-responding M3Da cells whereas neither Erk 1/2 nor p38
were activated in M1Dor cells (data not shown). However,
analysis of the implication of the p38-signalling pathway
using the specific pharmacological inhibitor SB203580,
clearly indicated that this cascade was not involved in IL-1b
regulation by EFs. Interestingly, the specific pharmacological
inhibitor U0126 (inhibiting MEK1-signalling pathway), did
not block either EFs effects on IL-1b expression but increased
it, suggesting that MAPK/Erk 1/2 was not involved in IL-1b
upregulation upon EFs treatment but interfered with other
signalling pathways. Accordingly, it has been shown that
the extramatricial molecule laminin, which share the same
receptor as elastin at the cell membrane (Mecham et al.,
1989) induces IL-1b gene expression by another signalling
cascade than the MAPK pathway. Moreover, Roman et al.
(1999) demonstrated that induction of the IL-1b gene by
several ECM molecules implied the transcription factor AP-1.
We also found that activation of the transcription factor AP-1
was associated with the activation of the MAPKs-signalling
cascades upon EFs stimulation in melanoma cells. In line
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Figure 6. EFs-enhanced binding of NF-jB on the promoter of IL-1b gene. (a) M3Da cells were stimulated with EFs for 2 hours prior chromatin extraction.
Chromatin was then fragmented and immunoprecipitated or not (as control) with an anti-p50 antibody; precipitated chromatin was then analyzed by PCR.
(b) Competition assays were performed between radio-labelled consensus sequences and specific unmarked probes for IL-1b gene enhancer element.
Oligonucleotides were incubated in presence of nuclear proteins from M3Da cells. Graphs express the ability for each probe to inhibit the protein binding on the
consensus site (in percentage of inhibition).
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with this result, this transcription factor has also been
involved in the MMP-1 upregulation following EFs fibroblast
stimulation (Duca et al., 2002). However, like for the MAPK
pathway, AP-1 DNA-binding analysis showed that this
transcription factor was not involved in IL-1b promoter
upregulation (see below). These discrepancies may be due
to the fact that Roman and co-workers considered the entire
ECM molecules that bind specific integrin receptors, whereas
in our model system, EFs engaged the elastin receptor (S-Gal)
and therefore different signalling cascades. In this setting, EFs
have been implicated in several biological effects, which
varied with the cell type studied; therefore it is not surprising
that these peptides activate several transduction pathways.
Then, although activation of the MAPK/AP-1 pathway is of
particular importance in cell proliferation and protease
release, activation of this cascade appears insufficient to
explain all EFs-induced biological activities related to cancer
progression observed in numerous cell types.
To our knowledge, up to now AP-1 was the only
transcription factor related to EFs stimulations. Here, we
provide evidence that NF-kB pathway is also activated in EFs-
responding cells (M3Da), confirming the fact that several
transduction cascades are activated by EFs treatment. In
keeping with the lack of EFs effects in M1Dor cells on IL-1b
regulation, we did not observed NF-kB activation although
NF-kB basal level was similar in the two cell line (data not
shown). Despite the fact that IL-1b gene expression implies
the complex interaction of several transcription factors such
as AP-1, cAMP response element-binding protein, and NF-kB
(Dinarello, 1996), our study shows that NF-kB-DNA binding
is responsible for the IL-1b promoter activation after EFs
stimulation. This was demonstrated at several levels: (i)
translocation of the NF-kB p50/p65 heterodimer in cells
nucleus, (ii) total inhibition of the EFs-increased IL-1b gene
transcription by specific NF-kB inhibitors such as the cell-
permeable peptide SN-50, or by infecting melanoma cells
with an Ad overexpressing IkB, (iii) increased NF-kB DNA
binding at the IL-1b promoter level by chromatin immuno-
precipitation. This latter demonstration was consistent with
the ability of the p50/p65 complex to regulate the IL-1b
promoter activity in the proximal region (Hiscott et al., 1993)
as well as in the distal part of the promoter containing
the enhancer element (Goto et al., 1999). Since both AP-1
and NF-kB nuclear-binding sites are present in the IL-1b
promoter, and that both transcription factors were activated
following EFs treatment, it was interesting to provide
information on the mechanisms driving the IL-1b expression.
Competition assays showed that despite the fact that both AP-1
and NF-kB transcription factors were activated, the distal
sequence of the IL-1b enhancer element, containing AP-1
and ‘‘NF-kB-like’’-binding sites in tandem, binds preferen-
tially NF-kB in M3Da melanoma cells. An explanation of the
predominant NF-kB DNA binding over AP-1 can be drawn
out of the structure analysis of the distal enhancer whose
sequence revealed that (i) the NF-kB sequence (3104-
AATAATTCC) is related to a RelA-binding site as compared to
already defined sequence in several cytokine (Lai et al.,
1995), (ii) the AP-1 sequence flanking the 50 extremity of
the NF-kB sequence of the IL-1b distal enhancer favors the
NF-kB DNA binding as it has already been shown in a
comparative study on a selection of kB/Rel DNA-binding
motifs (Kunsch et al., 1992) (Table 1). Our present results
altogether with our previous data showing that Erk 1/2
activation by EFs is dependent on the PKA-signalling pathway
activation (Duca et al., 2002), suggest that a potential
mechanism of NF-kB activation upon EFs stimulation could
be as follow: in resting cells, the PKA catalytic subunit is
maintained in an inactive form by binding to IkBa in the
cytoplasm; after EFs stimulation, IkBa phosphorylation could
rely either on the classical or atypical NF-kB cascades or on
p38 activation, leading subsequently to IkBa ubiquitination
and degradation. Concomitantly to IkBa degradation, PKAc
activation would phosphorylate and activate the p65 subunit
(Zhong et al., 1997). The associated Erk 1/2 activation upon
EFs treatment could also trigger MSK-1-mediated phosphor-
ylation of p65 in the nucleus as it has already be shown for
tumor necrosis factor-a-stimulated cells (Vermeulen et al.,
2003). These phosphorylations enhance p65 ability to recruit
the cAMP response element-binding protein and then
activate gene transcription. Therefore, EFs treatment could
activate several pathways such as Erk 1/2 and p38 and PKA to
mediate phosphorylation and activation of NF-kB.
It has been shown in previous studies that IL-1b could be
an important inducer of NF-kB during inflammation and
tumorogenesis (Shattuck et al., 1994; Wood and Richmond,
1995) and that deregulation of NF-kB were associated with
the constitutive expression of many chemokines responsible
of melanoma progression (Dhawan and Richmond, 2002).
We provide here evidences that EFs recruit NF-kB pathway
and participate to IL-1b upregulation in EFs-responding
invasive melanoma cells. The role of the pro-inflammatory
IL-1b in tumor progression is somewhat paradoxal. It has
been shown that IL-1b promotes tumor growth. Indeed, using
IL-1b knockout mice, Voronov et al. (2003) demonstrated
that local tumor or lung metastases of B16 melanoma cells
were IL-1 dependent. Since EFs treatment increase IL-1b
expression in B16 melanoma cells like in M3Da cells (data
not shown), it is tempting to hypothesize that in our model
system, EFs production which will induce overexpression of
IL-1 could participate to melanoma progression. By contrast,
other studies showed that IL-1b activates antitumoral
mechanisms through cytolytic activities of immune cells
Table 1. Comparative NF-jB DNA-binding motifs
(Kunsch et al., 1992)
NF-jB DNA-binding sequence
p50/p65
binding
IL-1b AGTGACTCAAGAGCTGAATAATTCCCCAAA
GTGACTCGCGGGGAATTCCGGCGAAGC ++++
GTGACTGATTGGGGGATTCCCGAAGC ++++
GCTTCGGGGATTCCTAGGCTGTCAC 7
GCTTCGACAAAGGGGATTCCCCGTCAC ++
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(Bjorkdahl et al., 2000) and induces IL-2 and IFN-g, two NF-
kB-dependent T-helper type-1 cytokines involved in tumor
growth inhibition (Gansbacher et al., 1990a, b; Lai et al.,
1995). Interestingly, in a recent study we demonstrated that
EFs induce T-helper type-1 lymphocyte polarization (Debret
et al., 2005). Therefore, and oppositely to the previous
hypothesis, it emerges from these considerations that EFs
production will reduce melanoma progression either directly
via T-helper type-1 lymphocyte orientation or indirectly
through IL-1b overexpression. These two hypotheses are
not incompatible and could intervene in different stages of
melanoma progression according to the presence or not of
infiltrated inflammatory cells in melanoma microenviron-
ment, concomitantly which elastin peptides and IL-1b.
In conclusion, we showed in this study the key role of EFs
in NF-kB-dependent cytokine gene expression involved in
melanoma regulation.
MATERIALS AND METHODS
Cell cultures
Melanoma cell lines (M1Dor and M3Da) were established from
metastases of two patients with malignant melanoma and have
been previously characterized. These cells were chosen in keeping
with their different ability to grow in nude mice after subcutaneous
grafting. The percentage of tumor taken in nude mice was 100% for
M3Da and 26% for M1Dor (Berthier-Vergnes et al., 1985). The two
tumor cell lines were grown as monolayer cultures in McCoy’s 5A
medium supplemented with 10% of heat-inactivated foetal bovine
serum (Gibco, Cergy-Ponthoise, France) in a humidified 95% air, 5%
CO2 atmosphere at 371C. A total of 20,000 cells per cm
2 were
initially seeded in plastic plates and grown until 80% confluence.
Cells were then washed twice with McCoy’s 5A medium alone and
serum starved for 16 hours prior treatments with k-elastin as EFs
(Menasche et al., 1981) or VGVAPG (Sigma, Saint-Quentin Fallavier,
France) at indicated times. All inhibitors, U0126 10 mM (Promega,
Lyon, France), SB203580 5 mM, lactose 10 mM (Sigma) were pre-
incubated for 1 hour. NF-kB inhibitors SN-50 and SN-50M were
purchased from Calbiochem (VWR, Fontenay sous Bois, France) and
used at a concentration of 50 mg/ml as described by Lin et al. (1995).
Human umbilical vein endothelial cells used as control in S-Gal
detection experiment were a kind gift of Dr A. Robinet from the
pharmacology department, Reims, France.
Reagents
TRI reagent was purchased from Euromedex (Molheim, France). Taq
DNA pol I, deoxynucleoside triphosphates, MgCl2 50 mM, Taq buffer
10 , primers specific for IL-1b and 18S cDNAs, primers specific for
IL-1b gene promoter used for electrophoretic mobility shift assay
competitions and primers specific for IL-1b gene promoter used for
chromatin immunoprecipitation PCR analyses were all provided by
Invitrogen (Cergy-Ponthoise, France). Anti-ERK 1/2, anti-Thr-202/
Tyr-204-phosphorylated ERK 1/2, anti-Thr-180/Tyr-182-phoshory-
lated p38 MAPK, anti-p65 were obtained from Cell Signaling
(Ozyme, Saint Quentin en Yvelines, France), anti-p50 was pur-
chased from Tebu-Bio (Santa-Cruz Biotechnology). Horseradish
peroxidase-anti-rabbit IgG secondary antibody and (g-32P)adenosine
50 triphosphate were from Amersham (Orsay, France), The NF-kB
(50-AGTTGAGGGGACTTTCCCAGGC-30) and AP-1 (50-CGCTTGAT
GAGTCAGCCGGAA-30) consensus oligonucleotides were obtained
from Promega (Lyon, France). Anti-p50 and anti-p65 used in
supershift assays and chromatin immunoprecipitation assays were
purchase from Santa Cruz (te´bu-bio, Le Perray en Yvelines, France).
Anti-S-Gal was provided by Neosystem (Strasbourg, France). Other
products used in these experiments were all obtained from Sigma
(Saint-Quentin Fallavier, France), except when indicated.
Anti-S-Gal preparation
The sequence VVGSPSAQDEASPL from alternatively spliced form
of human b-galactosidase (Privitera et al., 1998) was injected
intraperitoneally to rabbits. Antibodies were purified from antisera
on a sepharose-activated affinity column (Amersham) coupled with
the peptide. Specific antibodies were eluted with MgCl2 3 M.
Antibodies were then dialyzed overnight with phosphate-buffered
saline (Gibco). This antibody recognizes human, sheep, and bovine
S-Gal.
ELISA
After 6 hours incubation in presence or not of EFs, concentrations
of immunoreactive IL-1b in the cytoplasmic compartment of both
cell lines were measured using an ELISA according to instructions
provided by the manufacturer (R&D Systems, Lille, France). The
lower limit of ELISA sensitivity for IL-1b was 0.3 pg per well.
According to the manufacturer, there is no significant cross-reactivity
or interference with other known cytokines in this assay. Levels of
IL-1b were normalized for 106 cells.
RNA isolation and mRNA expression analysis
Total RNA was extracted using TRI Reagent. First-strand cDNA was
synthesized from 1 mg of total RNA using a Reverse Transcription
Kit (Euromedex) in 20 ml of reaction mixture, according to the
manufacturer’s instructions. The synthesized first-strand cDNA (1 ml)
was amplified by PCR in a final volume of 25 ml containing 10 mM
Tris-HCl, 2.5 MgCl2, 5% DMSO, 400mM deoxynucleoside tripho-
sphate, 10 pmol of each primer and 1 U of Taq DNA pol I. The
sequences of the primers for IL-1b and 18S RNA used were (sense)
50-TAC GAA TCT CCG ACC ACC ACT ACA G-30, (antisense) 50-GTA
CAG GTG CAT CGT GCA CAT AAG C-30, and (sense) 50-GCG AAT
TCC TGC CAG TAG CAT ATG CTT G-30, (antisense) 50-GGA AGC
TTA GAG GAG CGA GCG ACC AAA GG-30, respectively. PCR
amplifications of cDNA were performed under the following
conditions: 32 and 21cycles for IL-1b and 18S RNA, respectively,
1 minute at 951C, 1 minute at 651C, 30 seconds at 721C. Before the
first cycle, a denaturation step for 5 minutes at 951C was included,
and after the last cycle the extension was prolonged for 10 minutes at
721C.
Western blot analysis
Melanoma cell stimulation was stopped with ice-cold phosphate-
buffered saline containing 50mM of Na3VO4. Cells were washed
twice with the same buffer and scrapped in lysis buffer (phosphate-
buffered saline pH 7.4, 0.5% Triton X-100, 80 mM b-glyceropho-
sphate, 50 mM EGTA, 15 mM MgCl2, 1 mM Na3VO4 and protease
inhibitors cocktail), except for nuclear p50 and p65 blots (see below
for nuclear extraction in electrophoretic mobility shift assay
methods). Cancer cells were then sonicated. The homogenates were
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centrifuged 10 minutes (10,000 g), S-Gal present in the insoluble
fraction was resolved on a 10% SDS-polyacrylamide gel under
reducing conditions. Protein concentration of the soluble fraction
was measured with BC assay protein quantitation kit (Interchim,
Montluc¸on, France). Equal amounts of protein were separated by
10% SDS-polyacrylamide gels and transferred on to nitrocellulose
membranes. Even transfer was verified by Ponceau staining.
Membranes were blocked for 45 minutes at room temperature with
buffer containing 5% non-fatty milk in Tween-Tris-buffered saline
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.1% Tween 20). The
blots were incubated overnight with antibodies raised against ERK
1/2, Thr-202/Tyr-204-phosphorylated ERK 1/2, Thr-180/Tyr-182-phos-
horylated p38 MAPK, p65, p50 or S-Gal (10 mg/ml). After washing
the blots with Tween-Tris-buffered saline, they were incubated with
peroxidase-conjugated anti-(rabbit IgG) for 1 hour 30 minutes and
then washed again with Tween-Tris-buffered saline. Detection was
performed using ECLþ (Amersham, Orsay, France).
Electrophoretic mobility shift assays
Nuclear extracts were prepared from melanoma cells as already
described (Antonicelli et al., 2004). Briefly, cells were scraped and
lysed in 400 ml of buffer A (10 mM N-[2-hydroxyethyl]piperazine-N0-
[2-ethanesulphonic acid], 10 mM KCl, 2 mM MgCl2 1 mM dithiothrei-
tol, 0.1 mM EDTA, 0.4 mM phenylmethylsulfonyl fluoride, 0.2 mM
NaF, 0.2 mM Na3VO4, and 1 mg/ml leupeptin), to which was added
25 ml of buffer B (10% Nonidet P-40), and the nuclei were collected
by centrifugation (10,000 g for 2 minutes). Nuclei were resus-
pended in 50 ml of buffer C (50 mM N-[2-hydroxyethyl]piperazine-
N0-[2-ethanesulphonic acid], 50 mM KCl, 10% glycerol, 0.2 mM NaF,
and 0.2 mM Na3VO4) and agitated for 20 minutes at 41C, followed by
centrifugation (10,000 g for 5 minutes). Nuclear proteins (4mg)
were incubated with 5 binding buffer (50 mM Tris-HCl, 0.5 M KCl,
5 mM EDTA, 2.5 mM MgCl2, 40% glycerol) and (g-
32P)adenosine 50
triphosphate-labeled probes and were electrophoresed on a 6%
nondenaturing polyacrylamide gel. DNA binding on NF-kB and AP-1
consensus oligonucleotides was assessed by autoradiography.
Sequences of probes for competition assays were purchase from
Invitrogen and have been synthesized as follows. Probe 1 (50-AGTG
ACTCAAGAGCTGAATAATTCCCCAAA-30), Probe 2 (50-GAGCT
GAATAATTCCCCAAA-30). Probe 3 (50-GGCTTTAGTGACTCAAGA
GCTG-30).
Ad constructs
Ad overexpressing IkBa: Construction of the vector expressing a
mutant form of IkBa protein (in which serines 32 and 36 are replaced
by alanine residues (therefore preventing inducible IkBa phosphor-
ylation) has been described before (Jobin et al., 1997; Henriksen
et al., 2004).
The Ad-ovalbumin was a kind gift of Professor Z. Xing, Centre for
Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada.
The Ad-NF-kB-luciferase construct was obtained from the Gene
Transfer Vector Core, University of Iowa, USA.
All Ad constructs were titered conventionally (Graham and
Prevec, 1991) and were used on confluent M3Da cells at a
multiplicity of infection of 100. Ad vectors were pre-incubaked for
15 minutes at room temperature in McCoy’s 5A medium alone and
further incubated for 2 hours. Cells were then extensively washed
before replenishment with cell’s normal growth medium.
Chromatin Immunoprecipitation analysis
M3Da cells plated in 75 cm
2 flasks were fixed with 1% formalde-
hyde, neutralized with glycine for 5 minutes to a final concentration
of 125 mM, rinsed twice with Tris-buffered saline (100 mM NaCl,
50 mM Tris-HCl pH 8.1) and then scraped and syringed with Tris-
buffered saline containing 0.5% SDS. The cell pellet is resuspended
in the same buffer completed with 2% Triton X-100. The cell pellet
was sonicated to yield DNA fragments of B400 bp in average,
immunoprecipitated with 1mg of antibodies : anti-NF-kB-p50 and
rabbit anti-IgG antibody as negative control, or no antibody as
positive control (inputs), this last tube being conserved at 41C until
DNA isolation step. For the three other tubes, after overnight
incubation at 41C with continuous mixing, aggregates were removed
by centrifugation and protein-A beads were added to supernatant.
After 2 hours at 41C, immune complexes were collected by
centrifugation at 41C and washed three times with wash buffer
containing 150 mM NaCl, 20 mM Tris (pH 8.1), 5 mM EDTA (pH 8),
6% sucrose, 0.2% NaN3, 1% Triton X-100, 0.2% SDS, and twice
with solution containing 1 mM EDTA, 50 mM N-[2-hydroxyethyl]pi-
perazine-N0-[2-ethanesulphonic acid], pH 7.5, 500 mM NaCl, 1%
triton X-100, 0.2% NaN3, 0.1% deoxycholic acid, and twice with
LiCl detergent solution (10 mM Tris-pH 8, 1 mM EDTA-pH 8, 250 mM
LiCl, 0.2% NaN3, 0.5% NP-40, 0.5% deoxycholic acid), and finally
in TRIS–EDTA. All washes were 5 minutes at 41C with mixing. To
eluate immune complexes from beads, an incubation for 30 minutes
at 651C in reversal buffer (1% SDS, 100 mM NaHCO3) was carried
out. Eluate was then incubated overnight at 651C in the same buffer
to reverse crosslinks. DNA was extracted with phenol–chloroform
and precipitated with ethanol using glycogen as a carrier. The
purified DNA isolated by immunoprecipitation was analyzed by
PCR using (sense) 50-GGT AGA GAC CCA CAC CCT CA-30,
(antisense) 50-CAT GGA AGG GCA AGG AGT AG-30 primers for
the proximal IL-1b gene promoter; and (sense) 50-GCG AAG CCC
ATG ATT AGA CA-30, (antisense) 50-GAT CCC CAA TGA GCA GAA
AA-30 primers for the distal IL-1b gene promoter.
Statistical analysis
Experiments were performed at least twice in triplicate. Data are
reported as mean7SD. Statistical analysis was performed using
Student’s t-test. P-values of o0.05 were considered statistically
significant.
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